Results 141 to 150 of about 2,070,589 (168)

Effizienz und Sicherheit von 0.5 mg Ranibizumab verglichen mit einem intravitrealen Dexamethasone-Implantat (0.7 mg) bei Patienten mit Venenastverschluss

2014
Hintergrund: Behandlungsmöglichkeiten für VAV stellen die intravitreale Gabe von 0.5 mg Ranibizumab oder 0.7 mg Dexamethason-Implantat dar. COMRADE-B war eine prospektive, doppel-verblindete, randomisierte Phase-IIIb Studie um die Wirksamkeit und Sicherheit beider Behandlungsmöglichkeiten[for full text, please go to the a.m. URL]
Hattenbach, LO, Hoerauf, H, Eter, N, Lang, GE, Rehak, M, Wolf, A, Berk, H, Schmitz-Valckenberg, S, Feltgen, N   +8 more
openaire   +1 more source

[Treatment of postoperative cystoid macular edema (Irvine-Gass syndrome) with dexamethasone 0.7 mg intravitreal implant].

Journal francais d'ophtalmologie, 2016
To evaluate the efficacy of dexamethasone 0.7 mg intravitreal implant in patients with postoperative cystoid macular edema.Fourteen patients' charts with postoperative cystoid macular edema were retrospectively reviewed. The main outcome measures were best-corrected visual acuity (BCVA) and mean central retinal thickness (CRT).Patients' mean age was 72.
C, Landré, A, Zourdani, P, Gastaud, S, Baillif   +3 more
openaire   +1 more source

Sicherheit und Wirksamkeit von Ranibizumab (0.5 mg) im Vergleich zu Dexamethason (0.7 mg) bei Patienten mit Venenast- oder Zentralvenenverschluss: Langzeitergebnisse der COMRADE Extensionsstudie

2016
29.
Feltgen, N, COMRADE-Studiengruppe
openaire   +2 more sources

Isatuximab, Carfilzomib, and Dexamethasone in Relapsed Multiple Myeloma (IKEMA): A Multicentre, Open-Label, Randomised Phase 3 Trial

Lancet, The, 2021
Albert Oriol, Roman Hajek, Kenshi Suzuki
exaly  

Once-per-Week Selinexor, Bortezomib, and Dexamethasone Versus Twice-per-Week Bortezomib and Dexamethasone in Patients With Multiple Myeloma (BOSTON): A Randomised, Open-Label, Phase 3 Trial

Lancet, The, 2020
Roman Hajek, Thierry Facon, Athanasios Dimopoulos   +2 more
exaly  

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma (CANDOR): Results From a Randomised, Multicentre, Open-Label, Phase 3 Study

Lancet, The, 2020
Ola Landgren, Athanasios Dimopoulos, Katja Weisel   +2 more
exaly  

Dexamethasone in Hospitalized Patients With Covid-19

New England Journal of Medicine, 2021
John Kenneth Baillie, Edmund Juszczak, Lucy Chappell   +2 more
exaly  

Comparison of an Aprepitant Regimen With a Multiple-Day Ondansetron Regimen, Both With Dexamethasone, for Antiemetic Efficacy in High-Dose Cisplatin Treatment

Annals of Oncology, 2006
H J Schmoll, M S Aapro, M S Aapro
exaly  

Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study

Lancet, The, 2019
Roman Hajek, Ian Kerridge, Athanasios Dimopoulos   +2 more
exaly  

Dexamethasone Therapy for Bacterial Meningitis in Children

Lancet, The, 1993
U B Schaad
exaly